PolyPid falls on wider-than-expected quarterly loss

Polypid

12/02/2025 18:32

** U.S.-listed shares of Israel-based drug developer PolyPid  PYPD.O  fell 4.7% to $2.75 
    ** Company, which develops therapies to improve surgical outcomes, posts quarterly loss of
$1.13 per share vs analysts' estimate loss of 88 cents
    ** Says independent monitoring board recommended to conclude late-stage study of
experimental drug upon enrollment of 800 patients 
    ** PYPD is testing the treatment to prevent surgical site infections in patients undergoing
a type of abdominal cancer surgery 
    ** Expects to report data from the late-stage in the second quarter of 2025 and plans to
submit a marketing application to the FDA if the study meets the main goal 
    ** In the last 12 months, stock has fallen 48.7% 

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))